小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究*

doi:10.3969/j.issn.1672-5069.2023.01.007

Abstract

Abstract: Objective The purpose of this experiment was to explore the effect of berberine (BBR) on liver inflammation reaction and intestinal flora changes in rats with non-alcoholic fatty liver disease (NAFLD). Methods Forty-five SD rats were randomly divided into control, model and and BBR-intervened groups, with 15 rats in each group. The NAFLD models were established by high-fat die feeding. The liver pathological changes was observed, and fasting blood glucose (FPG), fasting insulin (FINS) levels and insulin resistance index (IRI) were detected by automatic biochemical analyzer. The fecal 16SrRNA sequence were detected, and serum interleukin-6 (IL-6), IL-10 and tumor necrosis factor-α (TNF-α) levels were detected by ELISA. Results At the end of 16 week experiment, the NAFLD model was successfully established as proved in two rats; at the end of the experiment, the liver steatosis and inflammatory reactions improved greatly in BBR-intervened rats as compared to in the model; serum ALT, AST and LDL levels in the BBR-intervened group were (78.0±6.0)IU/L, (119.6±8.8)IU/L and (61.3±5.0)mg/dL, significantly lower than [(211.5±9.0)IU/L, (312.6±9.7)IU/L and (97.6±8.9)mg/dL, respectively, P<0.05], while serum HDL level was (70.0±5.4)mg/dL, significantly higher than [(14.6±5.7)mg/dL, P<0.05] in the model; the FPG, FINS and IRI in BBR-intervened group were (4.1±0.5)mmol/L, (12.7±0.9) mU/L and (2.8±0.4), significantly lower than [(5.9±0.9)mmol/L, (19.3±1.1)mU/L and (4.6±1.0), respectively, P<0.05] in model; the fecal Lachnospira and Clostridium in BBR-intervened group were (5.6±0.5) and (2.0±0.4), significantly lower than[(13.4±1.3) and (7.2±0.6), P<0.05], while the Ruminococci and Lactic acid bacteria were (2.4±0.5 and (2.9±0.5), significantly higher than [(1.0±0.2) and (1.1±0.2), P<0.05] in the model; serum IL-6 and TNF-α levels in BBR-intervened group were (52.1±9.8)pg/mL and (70.0±17.3)pg/mL, both significantly lower than [(80.3±21.6)pg/mL and (120.8±22.6)pg/mL, P<0.05], while serum IL-10 level was (6.1±2.7)pg/mL, significantly higher than [(3.4±1.8)pg/mL, P<0.05] in the model. Conclusion The BBR could alleviate hepatic inflammatory reactions in rats with high-fat diet-induced NAFLD, which might be related to the regulation of intestinal floras.

Key words: Non-alcoholic fatty liver diseases, Liver inflammation, Berberine, Intestinal flora, High-fat diet, Rats

Huang Danxia, Zhao Zhihui, Xiao Yuexing, et al. Berberine improves liver injuries and intestinal flora disorders in high-fat diet-induced non-alcoholic fatty liver disease in rats[J]. Journal of Practical Hepatology, 2023, 26(1): 23-26.

References

[1] Schattenberg JM . Non-alcoholic fatty liver disease (NAFLD). MMW Fortschritte der Medizin, 2020, 162(4):56-62.
[2] Del CJ, Gallego DR, Paloma G, et al. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J Mol Sci, 2018, 19(3):911-916.
[3] Younossi ZM. Patient-reported outcomes and the economic effects of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis - the value proposition. Hepatology, 2018, 8(6):2405-2412.
[4] Panahi Y, Kianpour P, Mohtashami R, et al. Efficacyof artichoke leaf extract in non-alcoholic fatty liver disease: A pilot double-blind randomized controlled trial. Phytother Res, 2018, 32(7):1382-1387.
[5] Poudel A, Zhou JY, Mekala N, et al. Berberine protects against cytokine-induced inflammation through multiple pathways in undifferentiated C2C12 myoblast cells. Can J Physiol Pharmacol, 2019, 97(8):699-707.
[6] Xi X, Xiao PZ, Jin Y, et al. Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3. Faseb J, 2019, 33(6):7289-7300.
[7] Xiang X, Dan Y, Haobo L, et al. Enhancement of adiponectin ameliorates nonalcoholic fatty liver disease via inhibition of FOXO1 in type I diabetic rats. J Diab Res, 2018, 2018(8):1-9.
[8] Avshalom L, Ariel B, Mayan G, et al. Saccharin increases fasting blood glucose but not liver insulin resistance in comparison to a high fructose-fed rat model. Nutrients, 2018, 10(3):341-349.
[9] Li HS. Salidroside and curcumin formula prevents liver injury in nonalcoholic fatty liver disease in rats. Ann hepatol, 2018,17(5):769-778.
[10] Li ZL, Na Z, Yu W, et al. Mechanism of Yinchenhao decoction in treating non-alcoholic fatty liver based on 16S rRNA technique and metabonomics. Chin J Trad Chin Med Pharm, 2019, 34(5):1908-1913.
[11] Lu L, Yan L, Yuan J, et al. Shuganyin decoction improves the intestinal barrier function in a rat model of irritable bowel syndrome induced by water-avoidance stress. Chin Med, 2018, 13(1):6-11.
[12] Xiao L, Gao, Rui Z, et a. A study of the correlation between obesity and intestinal flora in school-agechildren. Sci Rep, 2018, 8(1):14511-14518.
[13] Mariana RB, Ratkovich GS, Alvarez ZM, et al. P172association between short-chain fatty acids producing bacteria and CD4 T cells recovery in HIV positive patients. Sex Tran Infec, 2019, 95(1):A131-138.
[14] Qi Z, Yan O Y, Bang H W, et al. Effects of dietary conjugated linoleic acid on growth performance, tissue adipocytokine levels and lipid metabolism of grass carp. Aquacult Nutr, 2018, 24(1):55-59.
[15] Xu ZJ, Fan JG, Ding XD, et al. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Digest Dis Sci, 2010, 55(4):931-940.
[16] Shi JC . Application ofserum ALT, AST and GGT detection in the diagnosis of liver diseases. China For Med Treat, 2019, 8(5):190-192.
[17] Marcelo R, PhilipC . Obesity, inflammation, Toll-like receptor 4 and fatty acids. Nutrients, 2018, 10(4):432-439.
[18] Peng CH, Lin HT, Chung DJ, et al. Mulberry leaf extracts prevent obesity-induced NAFLD with regulating adipocytokines, inflammation and oxidative stress. J Food Drug Anal, 2018, 26(2):778-787.
[19] Soderborg TK, Clark SE, Mulligan CE, et al. Author correction: the gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun, 2019, 10(1):22-29.
[20] Yin JL, Yu PZ, Yuan JD, et al. Chaihu-Shugan-San decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD rats via the NLRP3 inflammasome pathway. Evid Based Complement Alternat Med, 2018, 11(6):1-11.

Berberine improves liver injuries and intestinal flora disorders in high-fat diet-induced non-alcoholic fatty liver disease in rats

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xu Weiqiang, Liu Shuping, Li Xiaomeng. Risk factors of non-alcoholic fatty liver diseases in physical examination individuals [J]. Journal of Practical Hepatology, 2023, 26(1): 35-38.
[2]	Cai Yong, Li Jing, Ou Qin. Implications of serum omentin, retinol-binding protein-4 and propeptide of type I procollagen in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 800-803.
[3]	Fan Ye, Zhang Ximei, Zhang Yan. Clinical implication of serum cystatin C, lipoprotein α and nesfatin-1 levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 816-819.
[4]	Zeng Ting, Lei Xiangyang, Bai Xiaosu. Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(5): 624-627.
[5]	Nian Fulin, Lu Xiaolan. Non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(3): 314-317.
[6]	Luo Ke, Ding Li, Liu Mei. Serum miR-21 and miR-148b levels in patients with chronic hepatitis B and their predictive value for liver tissue inflammation grading and fibrosis staging [J]. Journal of Practical Hepatology, 2022, 25(3): 335-338.
[7]	Wang Shisong, Lin Huixiong, Zhang Taisheng, et al. Short-term observation of metformin and dapagliflozin combination therapy in the treatment of patients with T2DM and NAFLD and their impact on serum dipeptidyl peptidase 4 and C-peptide levels [J]. Journal of Practical Hepatology, 2022, 25(3): 379-382.
[8]	Liu Shangzhi, Zhang Zhiqiang, Li Shengjin. Protective mechanism of Danzhi Xiaoyao powder on hepatic damage in rats with D-galactosamine/lipopolysaccharides-induced acute liver injury [J]. Journal of Practical Hepatology, 2022, 25(2): 179-182.
[9]	Liang Yebei, Yang Chunguang, Wang Kunfeng, et al. Epidemiologic investigation of non-alcoholic fatty liver diseases in whole adults of Blang ethnicity in Yunnan province [J]. Journal of Practical Hepatology, 2022, 25(2): 223-226.
[10]	Mo Chaoyan, Yang Youqiang, Zhong Yuan, et al. Implication of serum resistin and retinol-binding protein 4 in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2022, 25(2): 231-234.
[11]	Wang Fang, Gao Xiaoxia, Wang Qingqiang. Short-term efficacy of Huanglian Jiedu decoction and probiotics supplement in intervention of patients with non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2022, 25(2): 235-238.
[12]	Huang Die, Tian Haoyu, Li Yiling. Serum markers in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2022, 25(2): 297-300.
[13]	Ren Jie, Hao Qiaoyun, Huang Chenghe, et al. Structure of intestinal flora changes in patients with non-alcoholic fatty liver disease and diabetes mellitus type 2 [J]. Journal of Practical Hepatology, 2022, 25(1): 54-57.
[14]	Li Jingwei, Wang Zixuan, Wang Mengyu, et al. Berberine suppresses hepatic steatosis by activation of KLF4 via targeting HDAC/H3K9ac in palmitic acid-induced HepG2 cells in vitro [J]. Journal of Practical Hepatology, 2021, 24(6): 790-794.
[15]	Shi Xueli, Zhang Wanli, Mao Jun. Serum IL-38 and β2GPI levels in rats with autoimmune hepatitis and their relationship with liver tissue lesions [J]. Journal of Practical Hepatology, 2021, 24(6): 803-806.